Challenges targeting cancer neoantigens in 2021: a systematic literature review

Chen, Ina; Chen, Mike Y.; Goedegebuure, S. Peter; Gillanders, William E.

doi:10.1080/14760584.2021.1935248

Cited by 19 publications

(10 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptide-based neoantigen vaccines have received most of the attention in the research area of personalized neoantigen vaccines due to their high specificity, economical manufacture and established safety record (Table 3). 177,303,304 The neoantigen peptides can be produced as genetically encoded long peptides or fused polypeptides and chemically synthesized short peptides. The peptides are subjected to affinity chromatography, sizeexclusion chromatography (SEC) or high-pressure liquid chromatography (HPLC) to obtain sterile, endotoxin-free products with a purity of >98%.…”

Section: Peptide Vaccinesmentioning

confidence: 99%

Neoantigens: promising targets for cancer therapy

Xie

Shen

Gao

et al. 2023

Sig Transduct Target Ther

248

150

View full text Add to dashboard Cite

Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by tumor cells as a result of various tumor-specific alterations, such as genomic mutation, dysregulated RNA splicing, disordered post-translational modification, and integrated viral open reading frames. Neoantigens are recognized as non-self and trigger an immune response that is not subject to central and peripheral tolerance. The quick identification and prediction of tumor-specific neoantigens have been made possible by the advanced development of next-generation sequencing and bioinformatic technologies. Compared to tumor-associated antigens, the highly immunogenic and tumor-specific neoantigens provide emerging targets for personalized cancer immunotherapies, and serve as prospective predictors for tumor survival prognosis and immune checkpoint blockade responses. The development of cancer therapies will be aided by understanding the mechanism underlying neoantigen-induced anti-tumor immune response and by streamlining the process of neoantigen-based immunotherapies. This review provides an overview on the identification and characterization of neoantigens and outlines the clinical applications of prospective immunotherapeutic strategies based on neoantigens. We also explore their current status, inherent challenges, and clinical translation potential.

show abstract

Section: Peptide Vaccinesmentioning

confidence: 99%

Neoantigens: promising targets for cancer therapy

Xie

Shen

Gao

et al. 2023

Sig Transduct Target Ther

248

150

View full text Add to dashboard Cite

show abstract

“…Indeed, neoantigen vaccine is considered as a promising next generation cancer treatment method that is tailored to each patient ( 21 ). Although its clinical effectiveness in tumor regression and prevention of relapse have been reported by multiple trials, prioritizing vaccine target neoantigens still remains as a major challenge ( 22 , 23 ). In fact, most pMHC pairs were incapable of stimulating T cell response, emphasizing need for immunogenicity prediction ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

DeepNeo: a webserver for predicting immunogenic neoantigens

Kim

Bang²,

Noh³

et al. 2023

Nucleic Acids Research

View full text Add to dashboard Cite

Non-self epitopes, whether originated from foreign substances or somatic mutations, trigger immune responses when presented by major histocompatibility complex (MHC) molecules and recognized by T cells. Identification of immunogenically active neoepitopes has significant implications in cancer and virus medicine. However, current methods are mostly limited to predicting physical binding of mutant peptides and MHCs. We previously developed a deep-learning based model, DeepNeo, to identify immunogenic neoepitopes by capturing the structural properties of peptide-MHC pairs with T cell reactivity. Here, we upgraded our DeepNeo model with up-to-date training data. The upgraded model (DeepNeo-v2) was improved in evaluation metrics and showed prediction score distribution that better fits known neoantigen behavior. The immunogenic neoantigen prediction can be conducted at https://deepneo.net.

show abstract

“…To produce an efficient, individualized cancer vaccine, specific genetic mutations in the cancerous cells are identified to produce neoantigens that could bind to T-cells and elicit an immune response in the patient more specifically than traditional systemic and local methods [37]. However, this treatment has faced challenges, such as a need to enhance the identification of potential genetic markers that could provide the specificity needed for cancer vaccines [23,65]. RNA vaccines targeting various cancers are in the development and undergoing clinical trials.…”

Section: Development Of Mrna Vaccines As Cancer Therapeuticsmentioning

confidence: 99%

A New Era of RNA Personalized Vaccines for Cancer and Cancer-Causing Infectious Diseases

Ayala Pazzi,

Vij,

Salhadar

et al. 2023

RNA Therapeutics - History, Design, Manufacturing, and Applications

View full text Add to dashboard Cite

RNA vaccines for cancer and cancer-causing infectious agents are recognized as new therapeutics and are perceived as potential alternatives to conventional vaccines. Cancer is a leading cause of death worldwide, and infections (certain viruses, bacteria, and parasites) are linked to about 15–20% of cancers. Since the last decade, developments in genomics methodologies have provided a valuable tool to analyze the specific mutations, fusions, and translocations of the driver genes in specific cancer tissues. The landscape of the mutations identified by genome sequencing and data analysis can be a vital route to personalized medicine. This chapter will discuss the present state of mRNA vaccine development and ongoing clinical trials in oncology.

show abstract

Challenges targeting cancer neoantigens in 2021: a systematic literature review

Cited by 19 publications

References 116 publications

Neoantigens: promising targets for cancer therapy

Neoantigens: promising targets for cancer therapy

DeepNeo: a webserver for predicting immunogenic neoantigens

A New Era of RNA Personalized Vaccines for Cancer and Cancer-Causing Infectious Diseases

Contact Info

Product

Resources

About